GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of reading non-peptide threads from 2024 and half of it aged badly — 17 comments in the full submission. View in context.
120
c/orforglipron·submitted 18 days ago by u/dilara_weiss

reading non-peptide threads from 2024 and half of it aged badly

Paperbranch of 7 comments

reading non-peptide threads from 2024 and half of it aged badly. Making the case below, and I expect to lose some of it in the comments. The no-timing-restriction thing is the part I would care about most in practice, and it barely gets mentioned here. Assumed the peptide purity conversations transferred and they do…

Read the full submission and all 17 comments →

This branch

7 comments, started 18 days ago
u/piotr_bruun15 points·18 days ago

Read both programme names carefully after mixing them up in a comment and being politely corrected.

replysharereportpermalink
[deleted]11 points·17 days ago

[deleted]

replysharereportpermalink
u/piotr_bruun6 points·17 days ago

I would not assume the tolerability profile transfers exactly. Similar class effects, different exposure profile.

replysharereportpermalink
u/first_hundred2 points·17 days ago

a non-peptide agonist does not degrade the way a peptide does

replysharereportpermalink
u/fabio_lehtinen1 point·17 days ago

a non-peptide agonist does not degrade the way a peptide does

Adding the standing caveat — unapproved, and research material is not for human use.

replysharereportpermalink
u/kenji_laurent1 point·17 days ago

Same view. The analytical problem is different enough that the usual purity discussions here do not transfer cleanly.

replysharereportpermalink
u/jonas_cardoso4 points·17 days ago

daily dosing changes adherence in both directions

replysharereportpermalink

← back to the whole thread

About c/orforglipron

The small-molecule oral: why a non-peptide agonist escapes the absorption problems of oral semaglutide, what the ATTAIN and ACHIEVE readouts showed, and what a pill with no refrigeration requirement would do to the entire supply conversation this site is built around.

21kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/orforglipron
c/orforglipron rules
  1. Small molecule, not a peptide. Purity discussion here is a different problem.
  2. Cite ATTAIN/ACHIEVE arms specifically when quoting numbers.
  3. Availability speculation must be flaired Speculation.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/phase_two_peteu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →